General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer
Last updated October 17, 2019
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
HIV-1 Infection
Last updated October 15, 2019
Delstrigo (doravirine/lamuvidine/tenofovir disoproxil fumarate)
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
HIV-1 Infection
Last updated October 15, 2019
Status:
Concluded without agreement
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Atherosclerotic cardiovascular disease
Last updated October 4, 2019
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Classic Hodgkin's Lymphoma
Last updated October 4, 2019
Status:
Concluded with an LOI
Manufacturer:
BGP Pharma ULC
Indication:
Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer
Last updated October 3, 2019
Status:
Concluded without agreement
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated September 27, 2019
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)
Last updated September 25, 2019
Status:
Concluded with an LOI
Manufacturer:
BGP Pharma ULC
Indication:
Febrile neutropenia in non-myeloid malignancies
Last updated September 23, 2019
Velphoro (sucroferric oxyhydroxide)
Status:
Concluded with an LOI
Manufacturer:
Vifor Fresenius Medical Care Renal Pharma
Indication:
Hyperphosphatemia, end-stage renal disease
Last updated September 17, 2019